hla-a Clinical Research Trials

Please select a valid location from the dropdown

Filter By

Clear all Advanced

Advanced Filters

Gender
Phase
Study Type
Sponsors
Accepts healthy volunteers
Online Trials
Age Group

Any (3)

Phase 1 (1)
Phase 2 (1)
Unknown (1)

Interventional (2)
Observational (1)

Adaptimmune (1)
Tizona Therapeutics, Inc (1)
University of Aarhus (1)

No (3)

No (3)

Adult (18+) (3)

I am/have/had

I am/have/hadsarcoidosis

I am/have/hadmetastasis

I am/have/hadsquamous cell carcinoma of head and neck

I am/have/hadmeasurable disease

I am/have/hadmetastatic head and neck carcinoma

I am/have/hadcns metastases

I am/have/hadHIV Infection

I am/have/hadchemotherapy regimen

I am/have/hadimmunodeficiency

I am/have/hadneck cancer

I am/have/hadsolid tumour

I am/have/hadhead and neck cancer

I am/have/hadsquamous cell carcinoma

I am/have/hadhepatitis b

I am/have/hadcancer

I am/have/hadgranulomatous disease

I am/have/hadmonoclonal antibody therapy

I am/have/hadpd-l1

I am/have/hadrecurrent disease

I am/have/hadmetastatic head and neck cancer

added new label for I am/have/had

I am looking for

I am looking forhepatitis b

I am looking forcyclophosphamide

I am looking formonoclonal antibodies

I am looking forpembrolizumab

I am looking forhla-g

I am looking forfludarabine

added new label for I am looking for

Advanced Filters

Found 3 clinical trials

We call this “infoimagery”. It is unique to every trial and is generated based on a trials specific data eg. therapeutic area, study type, phase etc. and the centerwatch system associates the information to a matching set of related symbols and icons.

What's this?

SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer

This is a study to investigate the efficacy and safety of ADP-A2M4 in combination with pembrolizumab in HLA-A*02 eligible and MAGE-A4 positive subjects with recurrent or metastatic Head and Neck cancer.

metastasis

squamous cell carcinoma of head and neck

measurable disease

metastatic head and neck carcinoma

cns metastases

0 views
19 Feb, 2024

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

This is a Phase 1, multicenter, open-label, multiple-dose, dose-escalation and dose-expansion study to evaluate the safety, tolerability, PK, and pharmacodynamics of TTX-080 monotherapy in subjects with advanced or metastatic solid tumors known to express HLA-G. This first-in-human (FIH) study has been designed to evaluate the safety, tolerability, and preliminary antitumor …

cancer

solid tumour

metastasis

measurable disease

hla-g

0 views
19 Feb, 2024

ACE and HLA Genotypes Predict Severity and Disease Progression in Danish Sarcoid Patients

Sarcoidosis is a multisystem granulomatous disease of unknown cause histologically characterized by noncaseating granulomas. Genetic factors affect disease course, which is highly variable and difficult to predict. This study aims to evaluate the predictive value of ACE and HLA genotypes on disease severity and progression in Danish patients with sarcoidosis.

granulomatous disease

sarcoidosis

0 views
19 Feb, 2024